DE602004028834D1 - Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität - Google Patents
Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilitätInfo
- Publication number
- DE602004028834D1 DE602004028834D1 DE602004028834T DE602004028834T DE602004028834D1 DE 602004028834 D1 DE602004028834 D1 DE 602004028834D1 DE 602004028834 T DE602004028834 T DE 602004028834T DE 602004028834 T DE602004028834 T DE 602004028834T DE 602004028834 D1 DE602004028834 D1 DE 602004028834D1
- Authority
- DE
- Germany
- Prior art keywords
- combination
- treatment
- vaspermeability
- chinazolin
- angiogenesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0316176A GB0316176D0 (en) | 2003-07-10 | 2003-07-10 | Combination therapy |
GB0406546A GB0406546D0 (en) | 2004-03-24 | 2004-03-24 | Combination therapy |
GB0407753A GB0407753D0 (en) | 2004-04-06 | 2004-04-06 | Combination therapy |
PCT/GB2004/002932 WO2005004870A1 (en) | 2003-07-10 | 2004-07-07 | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004028834D1 true DE602004028834D1 (de) | 2010-10-07 |
Family
ID=34068756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004028834T Active DE602004028834D1 (de) | 2003-07-10 | 2004-07-07 | Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität |
Country Status (15)
Country | Link |
---|---|
US (3) | US20060167027A1 (de) |
EP (1) | EP1648465B1 (de) |
JP (1) | JP2007526886A (de) |
KR (2) | KR20060033782A (de) |
AT (1) | ATE478671T1 (de) |
AU (1) | AU2004255022B2 (de) |
BR (1) | BRPI0412426A (de) |
CA (1) | CA2531862C (de) |
DE (1) | DE602004028834D1 (de) |
HK (1) | HK1089378A1 (de) |
IL (1) | IL172853A (de) |
MX (1) | MXPA06000114A (de) |
NO (1) | NO333122B1 (de) |
NZ (1) | NZ544458A (de) |
WO (1) | WO2005004870A1 (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
DE60134679D1 (de) | 2000-10-20 | 2008-08-14 | Eisai R&D Man Co Ltd | Stickstoff enthaltende aromatische Heterozyklen |
GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
JP2006517575A (ja) * | 2003-02-13 | 2006-07-27 | アストラゼネカ アクチボラグ | 組合せ療法 |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
WO2005004870A1 (en) * | 2003-07-10 | 2005-01-20 | Astrazeneca Ab | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
US20080113039A1 (en) * | 2004-03-23 | 2008-05-15 | Stephen Robert Wedge | Combination Therapy |
WO2006035204A2 (en) * | 2004-09-27 | 2006-04-06 | Astrazeneca Ab | Combination comprising zd6474 and an imatinib |
US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
EP1925676A4 (de) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | Testverfahren für die wirkung eines vaskularisierungsinhibitors |
GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
CN101316590B (zh) | 2005-11-07 | 2011-08-03 | 卫材R&D管理有限公司 | 血管生成抑制剂和c-kit激酶抑制剂的组合使用 |
EP1971338B8 (de) * | 2005-12-22 | 2011-09-21 | AstraZeneca AB | Kombination von zd6474 und pemetrexed |
ES2556173T3 (es) | 2006-05-18 | 2016-01-13 | Eisai R&D Management Co., Ltd. | Agente antitumoral para un cáncer de tiroides |
CN1899616A (zh) * | 2006-07-20 | 2007-01-24 | 中国人民解放军军事医学科学院生物工程研究所 | 非受体酪氨酸激酶c-Abl特异性抑制剂的新用途 |
US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
US20100092466A1 (en) * | 2006-09-29 | 2010-04-15 | Anderson Joseph Ryan | Combination of zd6474 and bevacizumab for cancer therapy |
EP2119707B1 (de) | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Zusammensetzung zur behandlung von nicht differenzierten formen von magenkrebsen |
JP2008291017A (ja) * | 2007-04-25 | 2008-12-04 | Nissei Marine Kogyo Kk | Wip1発現増強剤及び癌治療増感剤 |
CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
US20100075916A1 (en) * | 2008-09-05 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases |
US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
KR102204279B1 (ko) | 2013-05-14 | 2021-01-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지 |
EP3146334B1 (de) * | 2014-05-23 | 2019-08-14 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Verfahren zur bestimmung, ob ein patient nach einer strahlungstherapie eine reaktion erreicht |
RS63559B1 (sr) | 2014-08-28 | 2022-10-31 | Eisai R&D Man Co Ltd | Derivat hinolina velike čistoće i postupak za njegovu proizvodnju |
PL3263106T3 (pl) | 2015-02-25 | 2024-04-02 | Eisai R&D Management Co., Ltd. | Sposób tłumienia goryczy pochodnej chinoliny |
AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
EP1676845B1 (de) * | 1999-11-05 | 2008-06-11 | AstraZeneca AB | Neue Quinazolin-Derivate |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
NZ537753A (en) * | 2002-08-09 | 2008-04-30 | Astrazeneca Ab | Combination of ZD6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
JP2006517575A (ja) * | 2003-02-13 | 2006-07-27 | アストラゼネカ アクチボラグ | 組合せ療法 |
WO2005004870A1 (en) * | 2003-07-10 | 2005-01-20 | Astrazeneca Ab | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
US20080113039A1 (en) * | 2004-03-23 | 2008-05-15 | Stephen Robert Wedge | Combination Therapy |
WO2006035204A2 (en) * | 2004-09-27 | 2006-04-06 | Astrazeneca Ab | Combination comprising zd6474 and an imatinib |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
EP1971338B8 (de) * | 2005-12-22 | 2011-09-21 | AstraZeneca AB | Kombination von zd6474 und pemetrexed |
US20100092466A1 (en) * | 2006-09-29 | 2010-04-15 | Anderson Joseph Ryan | Combination of zd6474 and bevacizumab for cancer therapy |
-
2004
- 2004-07-07 WO PCT/GB2004/002932 patent/WO2005004870A1/en active Application Filing
- 2004-07-07 AU AU2004255022A patent/AU2004255022B2/en not_active Ceased
- 2004-07-07 BR BRPI0412426-0A patent/BRPI0412426A/pt not_active IP Right Cessation
- 2004-07-07 MX MXPA06000114A patent/MXPA06000114A/es active IP Right Grant
- 2004-07-07 KR KR1020067000464A patent/KR20060033782A/ko active Search and Examination
- 2004-07-07 AT AT04743275T patent/ATE478671T1/de not_active IP Right Cessation
- 2004-07-07 CA CA2531862A patent/CA2531862C/en not_active Expired - Fee Related
- 2004-07-07 EP EP04743275A patent/EP1648465B1/de active Active
- 2004-07-07 US US10/563,668 patent/US20060167027A1/en not_active Abandoned
- 2004-07-07 DE DE602004028834T patent/DE602004028834D1/de active Active
- 2004-07-07 NZ NZ544458A patent/NZ544458A/en not_active IP Right Cessation
- 2004-07-07 KR KR1020127017256A patent/KR20120093411A/ko not_active Application Discontinuation
- 2004-07-07 JP JP2006518352A patent/JP2007526886A/ja active Pending
-
2005
- 2005-12-27 IL IL172853A patent/IL172853A/en not_active IP Right Cessation
-
2006
- 2006-01-20 NO NO20060307A patent/NO333122B1/no not_active IP Right Cessation
- 2006-09-06 HK HK06109909.5A patent/HK1089378A1/xx not_active IP Right Cessation
-
2009
- 2009-11-24 US US12/624,760 patent/US20100215773A1/en not_active Abandoned
-
2011
- 2011-11-10 US US13/294,152 patent/US20120263802A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1648465B1 (de) | 2010-08-25 |
US20100215773A1 (en) | 2010-08-26 |
CA2531862C (en) | 2011-10-25 |
IL172853A (en) | 2012-05-31 |
AU2004255022A1 (en) | 2005-01-20 |
US20060167027A1 (en) | 2006-07-27 |
EP1648465A1 (de) | 2006-04-26 |
ATE478671T1 (de) | 2010-09-15 |
NO333122B1 (no) | 2013-03-04 |
JP2007526886A (ja) | 2007-09-20 |
US20120263802A1 (en) | 2012-10-18 |
HK1089378A1 (en) | 2006-12-01 |
MXPA06000114A (es) | 2006-04-27 |
KR20060033782A (ko) | 2006-04-19 |
CA2531862A1 (en) | 2005-01-20 |
AU2004255022B2 (en) | 2007-08-23 |
NO20060307L (no) | 2006-02-08 |
BRPI0412426A (pt) | 2006-09-05 |
NZ544458A (en) | 2009-04-30 |
IL172853A0 (en) | 2006-06-11 |
WO2005004870A1 (en) | 2005-01-20 |
KR20120093411A (ko) | 2012-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004028834D1 (de) | Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität | |
NO20051575L (no) | Bruk av quinazolinderivatet ZD6474 i kombinasjon med gemcitabin og valgfritt ioniserende straling i behandling av sykdommer forbundet med angiogenese og/eller okt kar-gjennomtrengelighet | |
DE602006020621D1 (de) | Kombination von zd6474 und pemetrexed | |
MXPA04004355A (es) | Tratamiento de combinacion que comprende zd6474 y un taxano. | |
CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης | |
HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
ATE447974T1 (de) | Kombinationstherapie mit azd2171 und 5-fu und/oder cpt-11 | |
MXPA05008583A (es) | Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. | |
NO20056171L (no) | Kombinasjonsterapi | |
NO20064754L (no) | Kombinasjonsterapi | |
ATE339209T1 (de) | Kombinationstherapie mit gemzitabin und zd6126 |